Western Regional Medical Center, Inc.
Welcome,         Profile    Billing    Logout  
 20 Trials 
12 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Weiss, Glen J
DUET-1, NCT05120271 / 2021-005086-41: BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

Recruiting
1/2
110
Europe, US
CAR-GPC3 T Cells, BOXR1030
Sotio Biotech Inc., SOTIO Biotech AG, SOTIO Biotech a.s.
Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
10/27
12/42
AGX101-001, NCT06440005: A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Recruiting
1
80
US
AGX101, ADC
Angiex, Inc.
Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma
07/25
07/27
Quan, Walter
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
Niu, Jiaxin
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc., Bristol-Myers Squibb
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
12/25
12/28
KEYNOTE F92, NCT05597839: Study of DF9001 in Patients With Advanced Solid Tumors

Recruiting
1/2
242
US
DF9001, pembrolizumab, KEYTRUDA®
Dragonfly Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult
08/25
11/27
NCT04370587: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting
1/2
64
US, RoW
T3011, T3011 + pembrolizumab
ImmVira Pharma Co. Ltd
Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
10/23
10/25
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
NCT04780217: Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
42
US
T3011
ImmVira Pharma Co. Ltd
Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, NSCLC, Ovarian Cancer, Endometrial Cancer
03/25
08/25
BDTX-4933-101, NCT05786924: A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

Active, not recruiting
1
100
US
BDTX-4933
Black Diamond Therapeutics, Inc.
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, Melanoma, Melanoma (Skin), BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Lung Cancer, Recurrent Melanoma, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
06/26
12/26
Lynch, Cynthia
ELONA, NCT05618613: Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

Active, not recruiting
1b
67
US
Elacestrant, RAD1901, Onapristone
Context Therapeutics Inc.
Breast Cancer
12/24
04/26
Waypa, Jordan
NOVA-II, NCT04088318: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Active, not recruiting
2
170
US, RoW
OQL011, Vehicle Ointment
OnQuality Pharmaceuticals (USA) LLC
Hand-Foot Skin Reaction (HFSR)
02/24
06/24
Kachaamy, Toufic
No trials found

Download Options